SCHEMBL18220192

SCHEMBL18220192

COCCNC(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N4CCOCC4)ccc3c2)n1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.55
ALDH1A1 P00352 7/20 0.55
KDM4E B2RXH2 5/20 0.55
MEN1 O00255 5/20 0.55
HPGD P15428 3/20 0.55
GAA P10253 2/20 0.55
MAPT P10636 2/20 0.55
USP2 O75604 1/20 0.55
HTT P42858 1/20 0.55
APP P05067 3/20 0.51
LMNA P02545 4/20 0.44
MITF O75030 1/20 0.44
MAPK1 P28482 1/20 0.44
MDM2 Q00987 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPC1 O15118 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25610089 0.95 APP (0.50) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL21226359 0.92 APP (0.46) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL18220188 0.92 APP (0.51) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL18220184 0.92 APP (0.50) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL23134972 0.90 APP (0.46) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL17099866 0.88 APP (0.55) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL17099870 0.88 APP (0.55) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL17099878 0.88 APP (0.55) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL24075821 0.88 APP (0.55) KMT2AALDH1A1KDM4EMEN1HPGD
SCHEMBL18220190 0.86 ALDH1A1 (0.48) KMT2AALDH1A1KDM4EMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10934264-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-02 US disclosed
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-04-23 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 KMT2A 4649/4885ALDH1A1 4151/4885KDM4E 4807/4885
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 KMT2A 4649/4885ALDH1A1 4151/4885KDM4E 4807/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 KMT2A 4649/4885ALDH1A1 4151/4885KDM4E 4807/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA KMT2A 4621/4885ALDH1A1 4226/4885KDM4E 4804/4885
US-10934264-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 KMT2A 4649/4885ALDH1A1 4151/4885KDM4E 4807/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA KMT2A 4621/4885ALDH1A1 4226/4885KDM4E 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.